Clinical outcomes of left bundle branch area pacing in heart failure patients with typical or atypical left bundle

Yonghong Yang1, Zijun Zhao1, Yushi Luo1

  • 1Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.

Kardiologia Polska
|April 17, 2026
PubMed

Insights

Left bundle branch area pacing (LBBAP) significantly improves cardiac remodeling and clinical outcomes in heart failure patients with typical left bundle branch block (t-LBBB). Patients with atypical LBBB (a-LBBB) showed poorer response to LBBAP.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • The diagnostic criteria for left bundle branch block (LBBB) can influence the effectiveness of left bundle branch area pacing (LBBAP).
  • Understanding the differential response to LBBAP based on LBBB classification is crucial for optimizing heart failure (HF) treatment.

Purpose of the Study:

  • To compare the echocardiographic and clinical outcomes of LBBAP in HF patients with typical LBBB (t-LBBB) versus atypical LBBB (a-LBBB).

Main Methods:

  • Ninety-seven HF patients (LVEF <50%) who underwent LBBAP were retrospectively analyzed.
  • Patients were classified into t-LBBB (n=82) and a-LBBB (n=15) groups based on Strauss criteria.
  • Baseline characteristics, pacing parameters, and clinical outcomes were compared between groups.

Main Results:

  • The t-LBBB group showed significant improvements in left ventricular dimensions and ejection fraction post-LBBAP.
  • Response rates (91.5% vs. 33.3%) and hyper-response rates (59.8% vs. 13.3%) were significantly higher in the t-LBBB group.
  • The t-LBBB group experienced lower rates of all-cause mortality, HF hospitalizations, and composite endpoints compared to the a-LBBB group.

Conclusions:

  • LBBAP demonstrates superior efficacy in reversing cardiac remodeling for HF patients with t-LBBB compared to those with a-LBBB.
  • LBBAP significantly improves clinical outcomes in HF patients with t-LBBB, including reduced mortality and hospitalizations.
  • The classification of LBBB is a critical factor in predicting the success of LBBAP in heart failure management.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
845
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
628
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
721